Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Res. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
PMCID: PMC2846106

Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1


Recent genome-wide association studies have linked the chromosome 15q24-25.1 locus to nicotine addiction and lung cancer susceptibility. To refine the 15q24-25.1 locus, we performed a haplotype-based association analysis of 194 familial lung cases and 219 cancer-free controls from the Genetic Epidemiology of Lung Cancer Consortium (GELCC) collection, and used proliferation and apoptosis analyses to determine which gene(s) in the 15q24-25.1 locus mediates effects on lung cancer cell growth in vitro. We identified two distinct subregions, hapL (P = 3.20 × 10−6) and hapN (P = 1.51 × 10−6), which were significantly associated with familial lung cancer. hapL encompasses IREB2, LOC123688,and PSMA4, and hapN encompasses the three nicotinic acetylcholine receptor subunit genes CHRNA5, CHRNA3,and CHRNB4. Examination of the genes around hapL revealed that PSMA4 plays a role in promoting cancer cell proliferation. PSMA4 mRNA levels were increased in lung tumors compared with normal lung tissues. Down-regulation of PSMA4 expression decreased proteasome activity and induced apoptosis. Proteasome dysfunction leads to many diseases including cancer, and drugs that inhibit proteasome activity show promise as a form of cancer treatment. Genes around hapN were also investigated, but did not show any direct effect on lung cancer cell proliferation. We concluded that PSMA4 is a strong candidate mediator of lung cancer cell growth,and may directly affect lung cancer susceptibility through its modulation of cell proliferation and apoptosis.


Lung cancer is the leading cause of cancer death in both men and women worldwide (1). Many factors contribute to the risk of lung cancer including tobacco smoke and genetic variations among populations. Tobacco smoke is well established as the major risk factor for lung cancer; however, only 10% to 15% of long-term smokers develop lung cancer in their lifetime, suggesting a genetic predisposition to the disease (2). Benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in tobacco smoke are two major carcinogens that cause DNA damage, oxidative stress, and inflammation, thus promoting the initiation and growth of lung tumors (3, 4). Nicotine in tobacco smoke is noncarcinogenic but highly addictive and acts through nicotinic acetylcholine receptors (nAChR). nAChRs are plasma membrane ion channels present in many tissues including the central and peripheral nervous systems and bronchial epithelial cells (58).

Both lung cancer and nicotine dependence studies have independently identified associations with the same variants of the 15q24-25.1 locus (912). Several highly significant single nucleotide polymorphisms (SNP) were identified in this locus, which spans a linkage disequilibrium block of ~240 kilobases and contains the genes IREB2, LOC123688, PSMA4, CHRNA5, CHRNA3, and CHRNB4. The CHRN genes encode for subunits of the nAChRs and were initially attractive candidates. Of the other genes in the locus, IREB2 encodes an iron regulatory protein 2 and plays a central role in maintaining cellular iron homeostasis (13), PSMA4 encodes a structural protein of the 20S proteasome core (14, 15), and LOC123688 is a hypothetical gene. It remains unclear whether the 15q24-25.1 locus has any direct or indirect effect on lung cancer susceptibility since many SNPs in this locus have high linkage disequilibrium. In the first scenario, a gene(s) in the 15q24-25.1 locus may regulate cell proliferation and/or apoptosis in the lung and thus predispose smokers to lung cancer. In the second scenario, polymorphisms in the locus may affect nicotine dependence and propensity to smoke, and thus increase the likelihood of developing lung cancer.

Based on our fine mapping analysis, we have systematically examined all of the six genes located in the 15q24-25.1 region for their role in regulating lung cancer cell growth in vitro. Via gene knockdown and apoptosis analyses, we showed that PSMA4 at the 15q24-25.1 locus has a role in modulating human lung cancer cell proliferation. We further showed that PSMA4 is required for proteasomal activities. Expression of PSMA4 was increased in lung tumors compared with matched normal lung tissues. Our results suggest that PSMA4 is a novel candidate gene that may contribute to lung cancer susceptibility.

Materials and Methods


Full-length cDNAs in cloning vectors encoding IREB2 (BC017880), LOC123688 (BC132753), PSMA4 (BC047667), CHRNA3 (BC001642), CHRNA5 (BC033639), and CHRNB4 (BC096080) were purchased from Open Biosystems, amplified by PCR, and subcloned into the BamH I and Xho I sites of pLenti6/V5-D-TOPO (pLV) vector (Invitrogen) to generate pLV-IREB2, pLV-LOC123688, pLV-PSMA4, pLV-CHRNA5, pLV-CHRNA3, and pLV-CHRNB4, respectively. PCR segments were confirmed by sequencing. Short hairpin RNAs in pLKO.1 lentiviral vectors for IREB2, LOC123688, PSMA4, and CHRNA5 knockdown were purchased from Open Biosystems.

Cell lines

Human non–small cell lung cancer (NSCLC) cell lines A549 and H1299 were maintained in RPMI1640 supplemented with 10% fetal bovine serum (FBS) and 2 mmol/L glutamine. 293T cells were maintained in DMEM plus 10% FBS. The human nontumorigenic bronchial epithelial cell line HBEC3KT was maintained in keratinocyte serum-free medium (with 50 Ag/mL bovine pituitary extract and 5 ng/mL epidermal growth factor; Invitrogen). All cells were grown at 37°C in a humidified incubator with 5% CO2.

Transfection, vira l packaging, and target cell infection

All transfections were performed using Lipofectamine 2000 (Invitrogen). To package lentiviral vectors, 293T cells were transfected with pLV or pLKO.1 vector along with pDMD Z6 and pΔ8.2. Thirty-six hours after transfection, the supernatant was harvested and spun at 3,000 rpm for 10 min at 4jC, and then incubated with target cells in the presence of 8 µg/mL polybrene (Sigma) for 24 h. Three days after infection, A549 cells were selected under 9 µg/mL blasticidin (Invitrogen) for 2 wk (for pLV positive cells) or 1 µg/mL puromycin (Sigma) for 3 d (for pLKO.1-positive cells), H1299 cells were selected under 6 µg/mL blasticidin for 2 wk or 1 µg/mL puromycin for 3 d, and HBEC3KT cells were selected under 6 µg/mL blasticidin for 2 wk. Antibiotic-resistant cells were pooled and expanded for further analysis under selective conditions.

Cell proliferation assay

Cells were seeded in a 96-well plate at 1,000 cells per well (100 µL aliquots) and cultured for a period of up to 4 d for A549 and 6 d for H1299. Viable cells were determined daily by MTT assay using the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer’s instructions. All assays were performed to measure proliferation in triplicate wells.

RNA extraction, reverse transcription, and RT-quantitative PCR

Total RNAs of paired normal lung and lung tumor tissues were obtained from the Tissue Procurement Core at WUSTL. Total RNAs of cultured cells were extracted using Trizol (Invitrogen). To generate cDNA, 1 µg of total RNA was reverse transcribed (RT) using ImProm-II RT system (Promega). Twenty-five nanograms of the cDNA was used in a 25 µL total volume reaction mixture containing SYBR Green PCR Master Mix (Bio-Rad) and primers, and then quantitative PCR (qPCR) was performed using MyiQ Single Color Real-time PCR Detection System according to the manufacturer’s protocol (Bio-Rad). All primers were designed using Primer 3. The primers were as follows, for IREB2: (forward) 5′-TTGTTGGAAGCTGCTGTACG-3′, and (reverse) 5′-GGAAAAAGGGCACTTCAACA-3′; for LOC123688: (forward) 5′-GGAACAAGCCTCTGCGTTAG-3′, and (reverse) 5′-GGCCATCTTTGGTTTTTGAA-3′; for PSMA4: (forward) 5′-GGAGCCAATACCTTGTGAGC-3′, and (reverse) 5′-CCAGCCAATGTACAGCAATG-3′; for CHRNA5: (forward) 5′-GTTCGTCCTGTGGAACACCT-3′, (reverse) 5′-TTCTCATCCACATCCACCAA-3′; for CHRNA3: (forward) 5′-TGTCTCAGCTGGTGAAGGTG-3′, and (reverse) 5′-CCATAGTCAGAGGGGTTCCA-3′; for CHRNB4: (forward) 5′-CCCAGCTTATCAGCGTGAAT-3′, (reverse) 5′-CAGGCGGTAATCAGTCCATT- 3′; and for β-actin: (forward) 5′-CAAGAGATGGCCAGGGCTGCT-3′, and (reverse) 5′-TCCTTCTGCATCCTGTCGGCA-3′. All qPCR reactions were performed in triplicate.

Caspase-3/7 activity assay

Apoptosis was determined using SendoLyteTM Homogeneous Rh110 Caspase-3/7 Assay kit (ANASPEC). Cells grown in 100-mm culture dishes were washed with PBS and collected by trypsinization. An aliquot containing 1 × 105 cells was precipitated and lysed in 150 µL 1× lyse buffer. Caspase-3/7 substrate solution (50 µL) was further added, and the reaction mixture was incubated at RT for 14 h. The end point fluorescence intensity was measured by a fluorescence microplate reader at Ex/Em of 496 nm/520 nm. All apoptosis assays were performed in triplicate.

Proteasome activity assays

The assay was performed as described (16) with modifications. Briefly, cells were washed with PBS and then collected with a rubber policeman in a lysis buffer containing 50 mmol/L Tris-HCl (pH 8.0), 5 mmol/L EDTA, 150 mmol/L NaCl, 0.5% NP40, 0.5 mmol/L DTT, and a protease inhibitor cocktail (Roche). The suspended cells were incubated on ice for 15 min with occasional vortexing. Lysates were spun at top speed in a microcentrifuge at 4°C for 20 min and supernatants were collected. An aliquot containing 100 µg of lysates was incubated with 20 mmol/L fluorogenic peptide substrates Suc-LLVY-AMC and Z-LLE-AMC (Calbiochem) in 100 µL for 90 min at 37°C. The end point fluorescence intensity was measured by a fluorescence microplate reader at Ex/Em of 380 nm/460 nm. All proteasome activity analyses were performed in triplicate.

Western blotting

Eighty to 90% confluent cells in each well of six-well plates were lysed in 250 µL of 1× LDS buffer (Invitrogen) containing proteinase and phosphatase inhibitor cocktails (Sigma), sonicated, and then boiled for 10 min. Twenty microliters of each sample were resolved on SDS-PAGE and immunoblotting analyzed with the indicated antibodies. Proteins were visualized with horseradish peroxidase–conjugated secondary antibodies (Amersham Biosciences) and an enhanced chemiluminescent substrate kit (Pierce).

Haplotype analysis of 15q24-25.1 locus

Haplotype-based association analysis was performed on the 15q24-25.1 locus using 194 familial lung cases and 219 cancer-free controls from the GELCC collections (12). A total of 251 SNPs spanning from 76,016,651 to 76,992,181 bases on the 15q24-25.1 locus were analyzed. To exhaustively exploit the haplotype information, we then subjected alleles (contiguous sets of markers) from sliding windows of all sizes to haplotype association tests. Haplotype analyses were implemented in the statistical package PLINK.12 Both omnibus/global association statistic and haplotype-specific statistic were computed. The haplotype-specific analysis tests each haplotype against all of the other haplotypes using χ2 with one degree of freedom (df). In total, H-1 haplotype–specific tests were performed at each location in which H was the number of haplotypes at that location. The omnibus association analysis jointly estimates all haplotype effects at a location using a single χ2 with H-1 df. At each location, the omnibus association analysis is first performed to assess the overall association. If the overall association is significant, then the haplotype-specific analysis will be performed to determine which haplotype at that location shows the strongest evidence for an association with familial lung cancer susceptibility.


Fine mapping of 15q24-25.1 locus

To refine the 15q24-25.1 locus, we performed haplotype-based association analysis using 194 familial lung cases and 219 cancer-free controls from the GELCC collections (Fig. 1). To exhaustively exploit the haplotype information, we analyzed haplotypes ranging from 3 to 15 contiguous SNPs in the 15q24-25.1 locus and identified two distinct subregions that showed the most significant associations with familial lung cancer. The subregion on the left side of the 15q24-25.1 locus (named hapL) encompasses eight SNPs (rs16969899, rs13180, rs16969914, rs9788682, rs9788721, rs8034191, rs10519203, and rs7163730) and spans 32.4 kb. Omnibus/global association analysis yielded a P value of 2.71 × 10−6 at hapL. Eight haplotypes were detected with frequencies of >1% at hapL. Among them, the haplotype ATAGCGCA showed the strongest association with familial lung cancer (P = 3.20 × 10−6). This haplotype is a risk allele with a frequency of 38.12% in cases versus 20.54% in controls, whereas three less common haplotypes, ATAGCGCG, ACAATATG, and ACAGTATA, reduce the risk of lung cancer (Table 1). The subregion on the right side of the 15q24-25.1 locus (named hapN) encompasses 12 SNPs (rs8040868, rs8192475, rs3743072, rs17487223, rs950776, rs11072768, rs11637890, rs11072773, rs12900519, rs12594550, rs12905641, and rs11857532) and spans 57.1 kb. The haplotype CCCGAACGCTGGC had the strongest association with familial lung cancer at hapN (P = 1.51 × 10−6).

Figure 1
Haplotype analysis of the 15q24-25.1 locus. A, association of haplotypes with familial lung cancer susceptibility in the GELCC collections. Blue lines, the results from omnibus/global haplotype analysis; red lines, the results from individual haplotype ...
Table 1
Two haplotypes are associated with familial lung cancer

On the 15q24-25.1 locus, IREB2, LOC123688, and PSMA4 are within or around hapL, whereas the nAChR subunit genes CHRNA5, CHRNA3, and CHRNB4 are within or around hapN. It is likely that the two subregions may have distinct roles in lung cancer susceptibility. Gene(s) around hapL may regulate cell proliferation and/or apoptosis in the lung and thus predispose smokers to lung cancer (a direct effect), whereas gene(s) around hapN may affect nicotine dependence and propensity to smoke and thus increase the likelihood of developing lung cancer (an indirect effect). nAChRs have previously been implicated in nicotine dependence and related phenotypes (912, 1719). The present study uses gene overexpression and/or gene knockdown and apoptosis analyses to determine if any gene(s) around hapL mediates effects on lung cancer cell growth in vitro.

IREB2, LOC123688, PSMA4,and lung cancer cell proliferation

To determine whether genes around the hapL play a role in regulating human lung cancer cell proliferation, IREB2, LOC123688, and PSMA4 were first overexpressed in A549 and H1299 cells. For unknown reasons, we could only increase the PSMA4 transcript levels up to 1-fold in both cell lines and the IREB2 transcript levels up to 1-fold in A549 (Supplementary Fig. S1). Consequently, we optioned to conduct gene knockdown experiments using short hairpin RNAs. Effective individual knockdown of IREB2, LOC123688, and PSMA4 in A549 and H1299 cells was examined by RT-qPCR (Fig. 2A, a). Next, we measured cell growth by MTTcell proliferation assay and found that LOC123688 knockdown had no effect on cell growth, whereas PSMA4 knockdown slowed down both A549 and H1299 cell proliferation compared with vector control cells (Fig. 2A, b). IREB2 knockdown in A549 cells slightly promoted cell growth, but had no effect on H1299 cell growth (Fig. 2A, b). We further tested to see if the growth inhibition was mediated through apoptosis and found that caspase-3/7 activity was only significantly increased in both A549 and H1299 cells when PSMA4 was knocked down (Fig. 2A, c). IREB2 and LOC123688 knockdown in A549 and H1299 cells did not affect apoptotic status in these cell lines (Fig. 2A, c). We also examined the effect of PSMA4 on nontumorigenic HBEC3KT, a human bronchial epithelial cell line. Overexpression of PSMA4 in HBEC3KT cells increased the transcript level of PSMA4 up to 9-fold (Fig. 2B, a), but not the rate of proliferation of HBEC3KT cells (Fig. 2B, b). Collectively, our data suggest that PSMA4 has a role in regulating human lung cancer cell proliferation and apoptosis.

Figure 2
Effects of IREB2, LOC123688, and PSMA4 on A549 and H1299 human lung cancer cell growth and apoptosis. A, effects of IREB2, LOC123688, and PSMA4 knockdown on A549 and H1299 human lung cancer cell growth and apoptosis. a, results of IREB2, LOC123688, and ...

CHRNA5, CHRNA3, CHRNB4,and lung cancer cell proliferation

To determine the candidacy of genes around the hapN and to see if they play a direct role in modulating cancer cell proliferation, CHRNA5, CHRNA3, and CHRNB4 were overexpressed in A549 and H1299 cells. RT-qPCR analysis revealed that overexpression of CHRNA5 in H1299 cells and overexpression of CHRNA3 and CHRNB4 in A549 and H1299 cells were significant, whereas overexpression of CHRNA5 in A549 cells was less efficient (Fig. 3A). MTT cell proliferation assays showed that the overexpression of these genes did not have significant and consistent effects on the regulation of A549 and H1299 cell growth compared with vector control cells (Fig. 3B).

Figure 3
CHRNA5, CHRNA3, CHRNB4, and human lung cancer cell proliferation. A, results of CHRNA5, CHRNA3, and CHRNB4 overexpression versus endogenous expression in A549 and H1299 cells by RT-qPCR analysis. Columns, mean −ΔCt values. The numbers ...

As the overexpression of CHRNA5 in A549 cells was not significant, we decided to use gene knockdown to explore the role of CHRNA5 on A549 cell growth. Successful CHRNA5 knockdown in A549 cells was examined by RT-qPCR (Fig. 3C). MTT cell proliferation analysis revealed that CHRNA5 knockdown did not alter A549 cell growth compared with vector control cells (Fig. 3D). Moreover, caspase-3/7 activity analyses showed similar enzyme activity between A549 vector control cells and A549 CHRNA5 knockdown cells, indicating that these cells had similar apoptotic statuses (Fig. 3E).

Taken together, our data show that altering the expression levels of CHRNA5, CHRNA3, and CHRNB4 do not affect A549 and H1299 cell proliferation, suggesting that these genes are not required to maintain cancer cell proliferation.

PSMA4-dependent proteasome activity

The 26S proteasome is a biological macromolecule consisting of a variety of structural and catalytic subunits. The 26S proteasome functions as multicatalytic proteinases containing chymotrypsin-like (CT-like) and peptidylglutamyl peptide hydrolyzing-like (PGPH-like) proteolytic activities. Altering the stoichiometry of the PSMA4 structural subunit with other proteasomal subunits may affect proteasomal proteolytic activities. We followed proteasomal CT- and PGPH-like proteolytic activities and examined the effect of PSMA4 knockdown on proteasome activities in A549 PSMA4 knockdown versus A549 vector control cells. Knocking down PSMA4 reduced proteasomal CT- and PGPH-like activities to 50% of that observed in vector control activities (Fig. 4A). This result showed that PSMA4 is required for maintaining normal proteasomal catalytic activities. A consequence of the decreased proteasome activity was an increase in the number of ubiquitinated proteins in A549 PSMA4 knockdown cells compared with A549 control cells (Fig. 4B).

Figure 4
PSMA4-dependent proteasome activity. A, effects of PSMA4 knockdown on 26S proteasome activity. Proteasomal CT-and PGPH-like activities were measured. Columns, mean proteasomal CT- or PGPH-like activities (RFU). B, the lysates used in Fig. 4A were resolved ...

Increased PSMA4 transcripts in human lung cancers

Although in vitro overexpression of PSMA4 yielded almost no increase in transcription levels, gene knockdown analysis, in turn, confirmed that PSMA4 plays a role in modulating cell proliferation. To see if the expression of PSMA4 is altered in human NSCLC, the abundance of PSMA4 transcripts in 52 paired human normal lung and lung tumor samples was examined by RT-qPCR. Of the 52 paired samples, 21 (40.4%) had increased levels (>1.5-fold) of PSMA4 transcripts in the tumor, 1 (1.9%) had decreased levels (<0.5-fold), and 30 (57.7%) had no change (0.5–to 1.5-fold; Fig. 5). These 52 paired samples include acinar adenocarcinoma, bronchioloalveolar adenocarcinoma, adenocarcinoma NOS, papillary adenocarcinoma, adenosquamous carcinoma, epidermoid squamous cell carcinoma, keratinizing squamous cell carcinoma, and squamous cell carcinoma NOS. The percentage of paired samples with increased PSMA4 transcripts in the tumors varied from 30% to 60% among different histologic types of lung cancer, except for papillary adenocarcinoma that only had a 20% increase (Fig. 5). As shown in Fig. 5, cell type seems important in terms of PSMA4 overexpression. However, except for one tumor sample from the subtype adenosquamous carcinoma showing decreased expression of PSMA4, all other samples from the different subtypes showed either no changes or increased expression in PSMA4. Thus, although PSMA4 expression varied considerably among different lung cancer subtypes, in general, tumor samples from these different lung subtypes tend to show increased expression of PSMA4 compared with their pair-matched normal tissues. This result indicates that, in vivo, expression of PSMA4 is up-regulated in almost half of all lung cancers.

Figure 5
RT-qPCR analysis of PSMA4 transcript levels using total RNA samples from 52 paired tumor and normal tissues of the lung. Columns, mean values of fold change in PSMA4 expression in lung tumor versus normal lung tissues of the same patient. ADD, acinar ...


Recent efforts to elucidate genetic factors in lung cancer susceptibility have identified the chromosome 15q24-25.1 locus (911). The 15q24-25.1 locus contains an iron metabolism protein gene IREB2, a 20S proteasome structural protein gene PSMA4, three nAChR subunit genes CHRNA5, CHRNA3, and CHRNB4, and a hypothetical gene LOC123688. An ongoing question is which among the six candidates accounts for an increased risk of lung cancer. In the current study, we have fine-mapped the 15q24-25.1 locus into two subregions: hapL for IREB2, LOC123688, and PSMA4; and hapN for CHRNA5, CHRNA3, and CHRNB4. Our in vitro investigation into the genes around hapL as modulators of tumor cell proliferation implicated PSMA4 as a strong candidate. This result is physiologically relevant for two reasons. First, there is endogenous expression of PSMA4 in the two human cancer cell lines used in this study, and second, expression of PSMA4 is upregulated in lung cancer as well as in other cancer types.

At present, there is no evidence that SNP status of these genes is directly linked to the mitogenic activity of their protein products. Haplotype or SNP data neither reflect genetic changes (such as at the mRNA/protein expression level or protein function) of the candidate gene(s) in detail, nor tell whether these genetic changes could alter biological functions. Identifying causal genetic variants in the candidate gene(s) is very challenging and requires further extensive genetic and biological investigations. Any genetic change will eventually be exhibited at the mRNA/protein level or protein function to play biological function. Therefore, in vitro changing gene expression levels via overexpression/knockdowns and assaying for proliferation and apoptosis would be more efficient and informative. By these approaches, we have shown that PSMA4 affects lung cancer cell proliferation and apoptosis. This result suggests that PSMA4 is a candidate lung cancer susceptibility gene in the 15q24-25.1 locus, although the other five candidate genes in this high linkage disequilibrium region cannot be completely excluded. Our in vitro analyses were limited to human lung cancer (lung cancer cell lines and lung cancer samples). However, the role of PSMA4 in leading tumorigenesis may not be limited to lung cancer. Similar to other oncogene/tumor suppressor genes, such as P53 and PTEN, elevated expression of PSMA4 is also found in other human cancer types.

The 26S proteasome contains one 20S proteasome core and two 19S regulatory caps. The 20S proteasome core is hollow and forms an enclosed cavity where proteins are degraded. The 20S proteasome core contains two types of subunits: α subunits are structural and serve as docking domains for proteasome assembly and regulators of proper function; β subunits are predominantly catalytic (14). PSMA4, a proteasome α type subunit 4, has been characterized as a structural subunit of the 20S proteasome core (14, 15). Our preliminary biological analysis revealed that PSMA4 governs proteasome activity. We showed in vitro that knockdown of PSMA4 expression decreases proteasome activity and results in the accumulation of ubiquitinated proteins. This proteasome is responsible for the degradation of proteins involved in the activation or repression of many cellular processes, including transcription, cell-cycle progression, and apoptosis. Therefore, proteasome dysfunction stresses cells. In our case, knockdown of PSMA4 expression in cancer cells induced apoptosis. Cancer cells show increased proliferation and decreased apoptosis in vivo via various mechanisms. Our findings that the down-regulation of PSMA4 expression induces apoptosis and that PSMA4 expression is increased in nearly half of the lung cancers studied suggest that upregulation of proteasome activity may be a novel mechanism of tumorigenesis. Indeed, inhibition or down-regulation of proteasome activity by proteasome inhibitors has already been adopted as a form of cancer treatment (20). Therefore, our findings strongly suggest that PSMA4 plays a direct role in cancer cell proliferation.

We also systemically evaluated the nAChR subunit genes, particularly CHRNA5, to determine if any of them has a regulatory effect on lung cancer cell growth. Recent studies have linked rs16969968, a missense SNP (D398N) in CHRNA5, to smoking, nicotine addiction, and lung cancer (12, 21). We overexpressed CHRNA5-D398 in parallel with CHRNA5-N398 (rs16969968) in A549 and H1299 cells and did not observe any difference in growth (data not shown). Collectively, our current biological analysis of the nAChR subunit genes around hapN did not reveal any growth or apoptotic differences between normal lung and lung cancer cells. Our data strongly suggest that these nAChR subunit genes are not directly involved in lung cancer, but may instead affect nicotine dependence and propensity to smoke and thus indirectly increase the likelihood of developing lung cancer.

In summary, we have shown for the first time that PSMA4 at the 15q24-25.1 locus plays a direct role in regulating lung cancer cell growth. Further understanding of the molecular mechanisms of the candidate genes may result in the development of new strategies for prevention, early detection, diagnosis, and treatment of lung cancer and other human cancers.

Supplementary Material

Supplementary Data


Grant support: NIH grants U01CA76293 (Genetic Epidemiology of Lung Cancer Consortium), R01CA058554, R01CA093643, R01CA099147, R01CA099187, R01ES012063, R01ES013340, R03CA77118, R01CA80127, P30ES06096, P50CA70907 (Specialized Program of Research Excellence), N01HG65404, N01-PC35145, P30CA22453, R01CA63700, DE-FGB-95ER62060, Mayo Clinic intramural research funds, and Department of Defense VITAL grant. This study was also supported in part by NIH, the Intramural Research Programs of the National Cancer Institute, and the National Human Genome Research Institute.

We thank the Fernald Medical Monitoring Program (FMMP) for sharing their biospecimens and data with us. We thank Dr. Jay W. Tichelaar and Dr. Haris G. Vikis for their critical comments on the manuscript, and Tiffany Wu and Kristen Baker for their English proofreading of the manuscript.


Note: Supplementary data for this article are available at Cancer Research Online (


Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.


1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. [PubMed]
2. Dubey S, Powell CA. Update in lung cancer 2007. Am J Respir Crit Care Med. 2008;177:941–946. [PMC free article] [PubMed]
3. Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res. 1999;424:127–142. [PubMed]
4. Mossman BT, Lounsbury KM, Reddy SP. Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am J Respir Cell Mol Biol. 2006;34:666–669. [PMC free article] [PubMed]
5. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7:833–839. [PubMed]
6. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest. 2002;110:527–536. [PMC free article] [PubMed]
7. Heeschen C, Weis M, Cooke JP. Nicotine promotes arteriogenesis. J Am Coll Cardiol. 2003;41:489–496. [PubMed]
8. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol. 1997;15:193–222. [PubMed]
9. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–642. [PubMed]
10. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40:616–622. [PMC free article] [PubMed]
11. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633–637. [PubMed]
12. Liu P, Vikis HG, Wang D, et al. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 2008;100:1326–1330. [PubMed]
13. LaVaute T, Smith S, Cooperman S, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet. 2001;27:209–214. [PubMed]
14. Nandi D, Woodward E, Ginsburg DB, Monaco JJ. Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor β subunits. EMBO J. 1997;16:5363–5375. [PubMed]
15. Davoli R, Fontanesi L, Russo V, et al. The porcine proteasome subunit A4 (PSMA4) gene: isolation of a partial cDNA, linkage and physical mapping. Anim Genet. 1998;29:385–388. [PubMed]
16. Eguchi H, Herschenhous N, Kuzushita N, Moss SF. Helicobacter pylori increases proteasome-mediated degradation of p27(kip1) in gastric epithelial cells. Cancer Res. 2003;63:4739–4746. [PubMed]
17. Berrettini W, Yuan X, Tozzi F, et al. α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13:368–373. [PMC free article] [PubMed]
18. Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165:1163–1171. [PMC free article] [PubMed]
19. Stevens VL, Bierut LJ, Talbot JT, et al. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev. 2008;17:3517–3525. [PMC free article] [PubMed]
20. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11:164–179. [PubMed]
21. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36–49. [PMC free article] [PubMed]